US Bancorp’s Takeda Pharmaceutical TAK Stock Holding History

US Bancorp’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.48M	Sell	466,714 -43,511	-9%	-$720K	0.01%	504
2026 Q1	$9.45M	Buy	510,225 +292,697	+135%	+$5.14M	0.01%	428
2025 Q4	$3.39M	Buy	217,528 +98,804	+83%	+$1.41M	﹤0.01%	715
2025 Q3	$1.74M	Buy	118,724 +6,250	+6%	+$92.8K	﹤0.01%	928
2025 Q2	$1.74M	Buy	112,474 +6,437	+6%	+$95.1K	﹤0.01%	907
2025 Q1	$1.58M	Sell	106,037 -18,295	-15%	-$256K	﹤0.01%	935
2024 Q4	$1.65M	Buy	124,332 +21,744	+21%	+$299K	﹤0.01%	943
2024 Q3	$1.46M	Buy	102,588 +10,925	+12%	+$155K	﹤0.01%	973
2024 Q2	$1.19M	Sell	91,663 -24,464	-21%	-$324K	﹤0.01%	1029
2024 Q1	$1.61M	Buy	116,127 +23,450	+25%	+$341K	﹤0.01%	920
2023 Q4	$1.32M	Sell	92,677 -3,784	-4%	-$53.7K	﹤0.01%	996
2023 Q3	$1.49M	Sell	96,461 -85,298	-47%	-$1.32M	﹤0.01%	900
2023 Q2	$2.86M	Sell	181,759 -41,113	-18%	-$674K	﹤0.01%	688
2023 Q1	$3.67M	Buy	222,872 +19,782	+10%	+$315K	0.01%	624
2022 Q4	$3.17M	Buy	203,090 +101,045	+99%	+$1.41M	0.01%	663
2022 Q3	$1.32M	Buy	102,045 +1,302	+1%	+$18.1K	﹤0.01%	936
2022 Q2	$1.41M	Sell	100,743 -22,985	-19%	-$328K	﹤0.01%	949
2022 Q1	$1.77M	Buy	123,728 +16,298	+15%	+$239K	﹤0.01%	937
2021 Q4	$1.47M	Buy	107,430 +28,301	+36%	+$397K	﹤0.01%	1041
2021 Q3	$1.3M	Buy	79,129 +24,849	+46%	+$417K	﹤0.01%	1060
2021 Q2	$914K	Buy	54,280 +113	+0.2%	+$1.92K	﹤0.01%	1244
2021 Q1	$989K	Buy	54,167 +6,960	+15%	+$125K	﹤0.01%	1138
2020 Q4	$859K	Buy	47,207 +1,896	+4%	+$33.3K	﹤0.01%	1163
2020 Q3	$808K	Buy	45,311 +6,103	+16%	+$111K	﹤0.01%	1087
2020 Q2	$703K	Buy	39,208 +7,096	+22%	+$127K	﹤0.01%	1117
2020 Q1	$487K	Sell	32,112 -13,771	-30%	-$250K	﹤0.01%	1208
2019 Q4	$905K	Sell	45,883 -5,438	-11%	-$104K	﹤0.01%	1095
2019 Q3	$882K	Buy	51,321 +8,006	+18%	+$138K	﹤0.01%	1090
2019 Q2	$766K	Sell	43,315 -13,483	-24%	-$245K	﹤0.01%	1192
2019 Q1	$1.16M	Buy	56,798 +43,748	+335%	+$880K	﹤0.01%	999
2018 Q4	$220K	Buy	+13,050	New	+$220K	﹤0.01%	1716

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

US Bancorp's TAK Position: Q2 2026 in Review

US Bancorp reduced its Takeda Pharmaceutical (TAK) stake by 8.5% in Q2 2026, selling an estimated $720K and leaving 466,714 shares worth $7.48M. The position accounts for 0.01% of the portfolio, ranked #504.

US Bancorp first reported a position in TAK in Q4 2018 and has held it in 31 quarters since. The position peaked at $9.45M in Q1 2026. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

US Bancorp held 466,714 shares of Takeda Pharmaceutical worth $7.48M as of Q2 2026.
US Bancorp sold 43,511 Takeda Pharmaceutical shares in Q2 2026, an estimated $720K.
Takeda Pharmaceutical made up 0.01% of US Bancorp's portfolio in Q2 2026, its #504 holding.
US Bancorp first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 31 quarters since.
US Bancorp's Takeda Pharmaceutical position peaked at $9.45M in Q1 2026.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.